Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.15) by $0.43. The firm earned $7.80 million during the quarter, compared to analysts' expectations of $8.32 million. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The firm's quarterly revenue was down 16.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) EPS. View Five Prime Therapeutics' Earnings History.

8 brokerages have issued twelve-month price objectives for Five Prime Therapeutics' shares. Their forecasts range from $39.00 to $94.00. On average, they expect Five Prime Therapeutics' stock price to reach $57.50 in the next year. View Analyst Ratings for Five Prime Therapeutics.

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:

• 1. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
• 2. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (5/2/2017)
• 3. Cowen and Company analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
• 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)

Some companies that are related to Five Prime Therapeutics include NovoCure Limited (NVCR), Aerie Pharmaceuticals (AERI), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN), Radius Health (RDUS), MyoKardia (MYOK), Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER) and Epizyme (EPZM).

Five Prime Therapeutics' management team includes the folowing people:

• Lewis T. Williams M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
• Marc L. Belsky, Chief Financial Officer, Senior Vice President
• Aron Marc Knickerbocker MBA, Chief Operating Officer, Director
• Kevin Baker Ph.D., Senior Vice President, Development Sciences
• Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer
• Francis Willard Sarena J.D., Chief Strategy Officer and Secretary
• Mark D. McDade, Lead Independent Director
• Garry Nicholson, Director
• Franklin M. Berger, Independent Director
• Fred E. Cohen Ph.D. M.D., Independent Director

Five Prime Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.48%), Vanguard Group Inc. (5.93%), State Street Corp (4.84%), Dimensional Fund Advisors LP (3.19%), BB Biotech AG (2.79%) and Victory Capital Management Inc. (2.39%). Company insiders that own Five Prime Therapeutics stock include Adage Capital Partners Gp Llc, Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Capital Fund Management S.A., Alliancebernstein L.P., Russell Investments Group Ltd., TIAA CREF Investment Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, OxFORD Asset Management LLP and FMR LLC. Company insiders that have sold Five Prime Therapeutics stock in the last year include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Insider Buying and Selling for Five Prime Therapeutics.

Five Prime Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Artal Group S.A., Victory Capital Management Inc., DekaBank Deutsche Girozentrale, State Street Corp, Pictet Asset Management Ltd., Williams Jones & Associates LLC and Marshall Wace North America L.P.. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Five Prime Therapeutics stock can currently be purchased for approximately $35.34.